Announcements Trials

Browse Landscape

Status

Approved for marketing 1

Sponsor Class

Study Type

Interventional 13 Expanded_access 1

Sponsor

Cancer Type

Conditions

Interventions

tazemetostat 2 regorafenib 2 nirogacestat 2 avapritinib 2 Trabectedin 2 selinexor 1 ripretinib 1 omburtamab I-131 1 olaratumab 1 mifamurtide 1 glucarpidase 1 ganitumab 1 fludarabine phosphate 1 balstilimab 1 anlotinib 1 Whole-Body Irradiation 1 Tacrolimus 1 TH 302 1 Sunitinib 1 Proton Pump Inhibitors 1 Mycophenolic Acid 1 Imatinib Mesylate 1 Hydrocortisone 1 FANG vaccine 1 Everolimus 1 DOXO-EMCH 1 Cytarabine 1 Cord Blood Stem Cell Transplantation 1 Carboxypeptidases 1 Busulfan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × olaratumab × Sarcoma × Clear all

NCT03994627 2024-12-16

Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Eli Lilly and Company

Approved for marketing

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡